Biotechna S.A.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2022-11-16
Share capital
127,883.00 PLN
Average employment (FTE)
38 (2025)
Activity description

Biotechna is an innovative biotechnology company focused on developing targeted therapies using nanotechnology, specifically for oncology. They have created a nanoparticle platform for the delivery of nucleic acids and small molecules, addressing various cancers such as breast, lung, and brain tumors. Additionally, they are advancing RNA and DNA-based products to target undruggable cancer types and enhance treatment effectiveness while reducing toxicity.

Registered address
ul. Bohdana Dobrzańskiego 3, 20-262 Lublin, Poland
Email
Social media
Electronic delivery address
AE:PL-38682-35987-HGWAA-23

Financials

Revenue history (in k)

From the notes

Current income tax (CIT due)$0
Profit allocationLoss to be covered
Capital expenditure$321,085
Planned capital expenditure (next year)$251,130
R&D costs$3,575,532
Contingent liabilitiesYes

Filing timeliness

1 of 4 financial statements was filed late (for 2022, 3 days late). All were audited by a statutory auditor.

  • 202509/07/2026
  • 202415/07/2025
  • 202310/07/2024
  • 202218/07/2023
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Top 8.8%
City · Lublin668 / 4,827
Top 14%
Voivodeship · Lubelskie1,756 / 10,168
Top 17%
Country · Poland53,767 / 297,069
Top 18%

Results vs industry

Revenue
This companyUSD 2.47mMedianUSD 56.72kAverageUSD 2.72m
Net profit
This companyUSD -1.33mMedianUSD -1.27kAverageUSD -93.01k
Operating costs
This companyUSD 3.60mMedianUSD 66.48kAverageUSD 2.68m
Assets
This companyUSD 3.95mMedianUSD 134.71kAverageUSD 3.04m

Offer

  • Biotechnology testing
  • Targeted therapy development
  • Oncological testing
  • RNA-based products
  • DNA-based products
  • Drug delivery systems
  • Nanoparticle platforms

Websites

The site is available in: Polish and English.

  • biotechna.comBIOTECHNA – SYNERGY to create hope
    WordPress 3.7ElementorYoast SEOPolylangCloudflare

Authorized Representatives

Riccardo Belli – Management Board Member
Sławomir Kościak age 42 – Management Board Member
Marcin Olczak age 49 – Management Board Member
Wojciech Smoroń age 43 – President of the Management Board

Manner of representation

In the case of a multi-member management board, each member of the management board is authorised to represent the company independently.

Supervisory board

Mohamed Mohamed Abdull Albanna – Supervisory Board Member
Algirdas Ziogas – Supervisory Board Member
Wojciech Bigaj age 50 – Supervisory Board Member
Mirosław Kuś age 56 – Supervisory Board Member
Łukasz Wawrykiewicz age 43 – Supervisory Board Member

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2019-07-04.

Debt

No entries in the National Debtors Register (KRZ).

MSiG notices

Publication dateEvent
Feb 18, 2025Commercial Companies Code notice
Nov 30, 2022Transformation registered

Public aid

7 public aid cases recorded, with a total value of $25,512,091.

PurposeGross amount
Aid for research and development projects: industrial research
$9.3M
Aid for research and development projects: experimental development
$1.3M
Aid for research and development projects: industrial research
$6.9M

European Funds

ProjectEU co-financing
KR2020 - Research and development of a first-in-class drug for use in non-small cell lung cancer
$11.1M

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
JJP Biologics sp. z o.o.
Poltreg S.A.
Captor Therapeutics S.A.
Molecure S.A.
SDS Optic S.A.
Śląski Park Technologii Medycznych Kardio-Med Silesia sp. z o.o.
Nanogroup S.A.
Oncotransfer sp. z o.o.
Famicordtx S.A.
Multiqure S.A.

Change history

DateEvent
2025-02-13Share capital increase
2025-02-13Name change
2024-11-06Share capital increase
2024-04-08Share capital increase
2023-07-21Share capital increase

FAQ

Last updated: 2026-07-15